Lucy’s story: 7 years of harmful cancer treatment under Prof Ian Brown

Despite guidelines recommending a maximum of six chemotherapy cycles, Lucy was prescribed over 75 across seven years — long after her scans showed no evidence of progression.
We make the difference. Talk to us: 0333 004 4488 | hello@brabners.com
The Personal Injury Discount Rate (PIDR) in England and Wales is increasing to +0.5% from 11 January 2025. This is a change from the current rate, which has been set at -0.25% since August 2019.
Here, Andrew Tindall from our medical negligence and serious personal injury team explains what the PIDR is and what this change means for those affected by serious personal injury.
The PIDR is a percentage that’s used to assess the amount of damages paid for future financial losses awarded (as a lump sum) to seriously injured individuals. This includes ‘heads of loss’ such as future care costs, medical expenses and lost income.
When an individual receives a large lump sum of compensation, that money can be invested and interest earned on it. The purpose of the PIDR is to adjust the award to account for these expected returns. With the correct amount of compensation and good investment, the individual should then have enough money to cover their needs for the rest of their life without being overcompensated and benefiting from their injuries.
The law assumes that those who’ve been injured shouldn’t take big investment risks. Therefore, the PIDR is set at a percentage rate to reflect the expected returns on very safe investments.
The current rate of -0.25% assumes very little investment growth on compensation awarded. As such, the amount of compensation awarded is higher because there’s an assumption that it will earn little to no interest from investments.
The new rate — which falls in-line with the current rate in Scotland and Northern Ireland — is higher, which assumes a slight increase on interest. The amount of money awarded will reduce as a result.
Take, for example, an injured individual who needs £1m over 20 years to cover their future expenses.
At -0.25%, the assumption is that there’ll be little to no growth on investment. Therefore, the lump sum would need to be around £1,020,000 to ensure that the money covers 20 years of expenses.
With a rate of +0.5%, the assumption is that there’ll be a modest investment return. This means that the sum awarded would be around £950,000, with the extra growth from investments expected to make up the difference.
The change in the PIDR increases the investment risk for injured individuals, highlighting the critical need for effective financial management to secure their long-term needs.
That’s why our serious injury team collaborates with reputable, independent financial advisers who specialise in personal injury compensation. This ensures that our clients benefit from tailored strategies that will minimise risk and safeguard their future.
The change in rate is also likely to lead to greater reliance on periodical payment orders (PPOs), which provide annual payments instead of a lump sum. PPOs help to mitigate the increased financial risks associated with reduced lump-sum awards — offering a more stable and predictable income. We’re also experienced in assessing the need for PPOs and can advise you accordingly.
We're trusted by clients and their families who’ve sustained serious injuries through no fault of their own where they were owed a duty of care by an individual, company or public sector organisation.
If you believe that you or someone you know may be entitled to compensation, talk to us by giving us a call, sending us an email or completing our contact form below.

Loading form...

Despite guidelines recommending a maximum of six chemotherapy cycles, Lucy was prescribed over 75 across seven years — long after her scans showed no evidence of progression.

Across the UK, neurosurgery and neuro-oncology services at several NHS Trusts have been subject to independent reviews, regulatory scrutiny and (in some cases) Police investigations.

Prolonged chemotherapy treatment at University Hospitals Coventry and Warwickshire has sadly had a devastating and irreversible impact on David's life.

Concerns about chemotherapy now point to systemic failings involving neuro-oncology clinicians, neurosurgeons, neuroradiologists and more at UHCW.

Patients affected by the extended use of adjuvant Temozolomide chemotherapy have received a letter from University Hospitals Coventry and Warwickshire NHS Trust.

As seen on ITV's Good Morning Britain, we're calling for an extended patient safety review and independent investigation into an unnecessary chemotherapy regime.

We’re the only solicitors to have been working with patients affected by Prof Ian Brown's long-term Temozolomide chemotherapy treatments since April 2024.

Recent revelations have raised concerns about patients who were subjected to prolonged temozolomide chemotherapy treatments at the University Hospitals of Coventry and Warwickshire NHS Foundation Trust.

From building a family to creating Wills and trusts, buying or selling property, land or a business, planning for your succession or dealing with a crisis, it helps to have ready access to a multidisciplinary legal team that can support you with whatever life throws your way.

Find out how the law works and the available routes to safeguard your clinical negligence compensation from financial settlements in divorce proceedings.

Fiona Tinsley and Bill Braithwaite explain the teamwork approach we adopt to support clients and their families who've suffered from a serious injury.

Ever more athletes are speaking out about the dangers of RED-S — a serious health issue that can do lasting damage.

Our team details what went wrong and how we went about securing compensation.

Our medical negligence team provided pro-bono legal support to the family of a young man who was considered brain-dead.

Our medical negligence team achieved an out of court settlement for a client who underwent unnecessary vein surgery.

Our medical negligence team helped a client to achieve a six-figure settlement for a delay in diagnosis and treatment.

Our medical negligence team helped a 68-year-old man to be awarded £380,000 for a terminal oesophageal cancer diagnosis.

If your child has been impacted by lack of screening, delayed treatment or improper diagnosis, we can help.